vimarsana.com

Page 11 - ப்ரிந்ஸெஸ் அரச மருத்துவமனை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Measures in place to manage delays in ambulance handovers at Shropshire s hospitals, bosses say

Investigation after feeding tube inserted into patient s lung cavity at Telford hospital

Hospital Asks Midwives to Stop Using Terms Breastfeeding, Breast Milk to Be More Inclusive

Hospital Asks Midwives to Stop Using Terms Breastfeeding, Breast Milk to Be More Inclusive On 2/11/21 at 12:34 PM EST A U.K. hospital has issued new guidelines encouraging midwives to stop using terms such as breastfeeding and breast milk in an effort to be more inclusive of transgender and nonbinary people. The Brighton and Sussex University Hospitals NHS Trust (BSUH), a regional teaching hospital working across two sites, is urging staff to use phrases such as birthing parents and human milk instead of language that addresses only women. At BSUH we acknowledge the additional challenges that gender identity can have on pregnancy, birth and infant feeding. We recognize the importance of providing inclusive, respectful perinatal care to all pregnant people and their families, BSUH said in a statement published on its website in January.

AstraZeneca races to adapt Covid vaccine as South Africa suspends rollout

Covid-19 news archive: January 2021

Virginia Mayo/AP/Shutterstock Vaccines from Johnson & Johnson and Novavax report positive trial results A coronavirus vaccine developed by the US firm Novavax has been shown to be 89 per cent effective in preventing covid-19 in clinical trials. The trials included participants in the UK and South Africa, and found the vaccine to be 86 per cent effective against the UK variant of the virus, but only 60 per cent effective against the variant in South Africa. Novavax said it will immediately begin development on a vaccine specifically targeted to the South African variant. Advertisement Janssen, a subsidiary of US firm Johnson & Johnson, announced that its covid-19 vaccine showed 66 per cent efficacy in an international trial. These results are based on a single dose of the vaccine, which makes it easier to administer than the two-shot vaccines that have already been approved. The company has said it will sell its vaccine on a not-for-profit basis.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.